Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed's Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss' presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Bliss will provide an overview of the Company's clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.

Mr. Bliss's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical compa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 As part of ... Center (BDWMC), Sun Health Foundation funded a $3.25 million ... inpatient pharmacy with the most up-to-date features and technology. ... 2. The pharmacy's 45 staff members will begin moving ... space in the coming days. , The current ...
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... , May 20, 2015 Research and Markets ... the "Top Technologies in HW_Technical Insights" report ... this report evaluated technology trends in the Health and ... are likely to have an impact in the year ... of the top 10 health and wellness technologies that ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2
... MUNICH, Feb. 1, 2012  Exosome Diagnostics GmbH, a ... of Dermatology at the Ludwig Maximilian University (LMU) ... grant from the German Federal Ministry for Education ... from the stable RNA content accessible in plasma-derived ...
... WASHINGTON and SAN DIEGO, Feb. 1, 2012 /PRNewswire-iReach/ ... will be exhibiting at the CRT 2012 Conference in ... showcase its new cardiovascular diagnostic test PREvent. PREvent is ... the market that predicts near term (2-3 years) risk ...
... 2012   PAREXEL International Corporation (NASDAQ: ... today that it has entered into an agreement with ... Korea. The alliance offers clinical trial sponsors based regionally ... services throughout Asia , with a focus on ...
Cached Biology Technology:EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics 2EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics 3EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics 4FirstMark to Exhibit at Cardiovascular Research Technologies (CRT) 2012 Conference 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 3PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 4PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 5
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading cloud-based ... to more fully engage with their communities around health ... privacy protected and secure API.  ... the most accessible, affordable, and convenient vehicle to receive ... The API will allow higi,s ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... Managing plant diseases that threaten the food supply ... world. Sparsely stocked libraries, scarce and expensive software, ... languages are barriers to training plant pathologists in resource-poor ... University professor and her colleagues is bridging that gap. ...
... materials have garnered great interest worldwide due to ... medical and consumer applications. Singapore,s Institute ... new environmentally friendly method to synthesize a wide ... has been recently published in Nature Materials ...
... LAFAYETTE, Ind. - Using a diverse herbicide application strategy ... study shows the practice will drastically reduce weeds and ... Excess usage of glyphosate-resistant crops has led to weeds, ... the herbicide used in Roundup. Bill Johnson, a Purdue ...
Cached Biology News:K-State plant pathologists develop online teaching modules used globally 2Facile synthesis of nanoparticles with multiple functions advanced in Singapore 2Herbicide diversity needed to keep Roundup effective 2
... Antibody against TATA Binding Proteins (TBP). Ascites ... TBP and recognizes amino acids 41-57 and ... fragmentation of TBP occurs. This antibody ... (prepared either as a nuclear extract or ...
... This thin foil heat sealing material ... pressure from a screw down heated ... is a useful method for sample ... over the existing seal. Ideal for ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
... The CHEMICON Re-Blot Plus Western Blot Strong ... of antibodies from Western blots that have ... or other isotopes. It is not recommended ... etc.), as it is not possible to ...
Biology Products: